NASDAQ:LABP Landos Biopharma (LABP) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$22.75▼$22.9450-Day Range$21.51▼$22.9352-Week Range$2.50▼$22.94Volume50,800 shsAverage Volume19,700 shsMarket Capitalization$71.77 millionP/E RatioN/ADividend YieldN/APrice Target$20.42 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends Get Landos Biopharma alerts: Email Address Ad Crypto 101 MediaBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.Click here to get The Crypto Bull Run Millionaire Blueprint now. About Landos Biopharma Stock (NASDAQ:LABP)Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia.Read More Ad American Hartford Gold GroupPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE LABP Stock News HeadlinesMay 23, 2024 | prnewswire.comAbbVie Completes Acquisition of Landos BiopharmaMay 11, 2024 | businesswire.comLANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABPJuly 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.May 9, 2024 | investorplace.comLABP Stock Earnings: Landos Biopharma Misses EPS for Q1 2024April 26, 2024 | msn.comEx-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit OutlookApril 17, 2024 | msn.comLandos Biopharma (LABP) Price Target Increased by 154.20% to 12.96April 16, 2024 | prnewswire.comStockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVieMarch 27, 2024 | businesswire.comLANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABPJuly 26, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.March 27, 2024 | finanznachrichten.deLandos Biopharma, Inc.: AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesMarch 27, 2024 | markets.businessinsider.comLeerink Partners Remains a Hold on Landos Biopharma (LABP)March 26, 2024 | prnewswire.comSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Landos Biopharma, Inc - LABPMarch 26, 2024 | markets.businessinsider.comAbbVie To Acquire Landos Biopharma At $20.42/share In CashMarch 26, 2024 | bizjournals.comAbbVie to buy Landos Biopharma for $137 millionMarch 26, 2024 | finance.yahoo.comWhy Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?March 25, 2024 | investorplace.comWhy Is Landos Biopharma (LABP) Stock Up 168% Today?March 25, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Landos Biopharma, Inc. has obtained a Fair Price in its transaction with AbbVieMarch 25, 2024 | businesswire.comLABP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Landos Biopharma, Inc. Is Fair to ShareholdersSee More Headlines Receive LABP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Landos Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LABP CUSIPN/A CIK1785345 Weblandosbiopharma.com Phone540-218-2232FaxN/AEmployees19Year FoundedN/APrice Target and Rating Average Stock Price Target$20.42 High Stock Price Target$20.42 Low Stock Price Target$20.42 Potential Upside/Downside-10.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-73.00% Return on Assets-63.00% Debt Debt-to-Equity RatioN/A Current Ratio4.43 Quick Ratio4.43 Sales & Book Value Annual Sales$18 million Price / Sales3.99 Cash FlowN/A Price / Cash FlowN/A Book Value$7.41 per share Price / Book3.09Miscellaneous Outstanding Shares3,130,000Free Float3,085,000Market Cap$71.77 million OptionableNot Optionable Beta0.14 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Gregory Oakes (Age 55)President, CEO & Director Comp: $1.05MDr. Fabio Cataldi M.D. (Age 56)Executive VP & Chief Medical Officer Comp: $732.29kMs. Jennifer Creel (Age 53)Interim Chief Financial Officer Ms. Rebecca Mosig Ph.D.Vice President of Corporate DevelopmentDr. Josep Bassaganya-Riera DVM (Age 49)Ph.D., Advisor Comp: $1.79MKey CompetitorsAchilles TherapeuticsNASDAQ:ACHLAspira Women's HealthNASDAQ:AWHTherapeuticsMDNASDAQ:TXMDSensei BiotherapeuticsNASDAQ:SNSEAdverum BiotechnologiesNASDAQ:ADVMView All CompetitorsInstitutional OwnershipVirtu Financial LLCBought 14,537 shares on 5/20/2024Ownership: 0.464%Black Maple Capital Management LPBought 10,405 shares on 5/16/2024Ownership: 0.332%View All Institutional Transactions LABP Stock Analysis - Frequently Asked Questions How were Landos Biopharma's earnings last quarter? Landos Biopharma, Inc. (NASDAQ:LABP) released its quarterly earnings data on Thursday, May, 9th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($1.00) by $0.43. When did Landos Biopharma's stock split? Landos Biopharma shares reverse split on Friday, May 26th 2023. The 1-10 reverse split was announced on Friday, May 26th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Landos Biopharma IPO? Landos Biopharma (LABP) raised $101 million in an IPO on Thursday, February 4th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and SVB Leerink acted as the underwriters for the IPO and Raymond James was co-manager. This page (NASDAQ:LABP) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Landos Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Landos Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
